Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneFerm Biotechnology Co's quarterly market cap
increased
from Jun. 2025 (NT$1,824.2 Mil) to Sep. 2025 (NT$2,379.8 Mil) but then
declined
from Sep. 2025 (NT$2,379.8 Mil) to Dec. 2025 (NT$2,000.4 Mil).
GeneFerm Biotechnology Co's annual market cap
declined
from Dec. 2023 (NT$3,088.8 Mil) to Dec. 2024 (NT$1,948.6 Mil) but then
increased
from Dec. 2024 (NT$1,948.6 Mil) to Dec. 2025 (NT$2,000.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GeneFerm Biotechnology Co's Enterprise Value for Today is NT$1,345.8 Mil.
GeneFerm Biotechnology Co (ROCO:1796) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GeneFerm Biotechnology Co Market Cap Related Terms
GeneFerm Biotechnology Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GeneFerm Biotechnology Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneFerm Biotechnology Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GeneFerm Biotechnology Co's Market Cap distribution charts can be found below:
* The bar in red indicates where GeneFerm Biotechnology Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneFerm Biotechnology Co (ROCO:1796) has a Market Cap of NT$1,301.8 Mil as of Jul. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GeneFerm Biotechnology Co and its competitors. According to the industry distribution chart, GeneFerm Biotechnology Co ranks #727 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is GeneFerm Biotechnology Co's Market Cap too high?
GeneFerm Biotechnology Co's current Market Cap is NT$1,301.8 Mil. Based on the distribution chart, GeneFerm Biotechnology Co ranks #727 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GeneFerm Biotechnology Co ranks #727 out of 1022 companies for Market Cap. This places GeneFerm Biotechnology Co in the lower half of its industry. The industry median Market Cap is 220.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 220.60, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GeneFerm Biotechnology Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 220.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneFerm Biotechnology Co's current Market Cap is NT$1,301.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.04, compared to a current price of NT$31.40 — trading 46.8% below its estimated fair value. The current Market Cap is NT$1,301.8 Mil. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current Market Cap is NT$1,301.8 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued.
The current stock price of NT$31.40 is trading 46.8% below its estimated GF Value™ of NT$59.04.
GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:1796:
Market Cap: NT$1,301.8 Mil
GF Value™: NT$59.04 vs. price of NT$31.40 (46.8% below fair value)
No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score
Get the complete analysis for ROCO:1796
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1796 has been successfully added to your 
